



Proventil® HFA (albuterol) – First-time generic (authorized generic)

- On April 5, 2019, [Endo announced](#) that one of its operating companies, Par, launched an authorized generic version of Merck's [Proventil HFA \(albuterol\)](#) inhalation aerosol.
- Proventil HFA is indicated in adults and children 4 years of age and older for the treatment or prevention of bronchospasm with reversible obstructive airway disease and for the prevention of exercise-induced bronchospasm.
- Albuterol is also available generically as oral [tablets](#), oral [extended-release tablets](#), oral [syrup](#), inhalation nebulizer [solution](#), and combination [ipratropium/albuterol](#) inhalation solution; and as an authorized generic inhalation [aerosol](#); and as a branded inhalation powder ([ProAir Respiclick®](#)).
 - Albuterol tablets and extended-release tablets are approved for the relief of bronchospasm in adults and children 6 years of age and older with reversible obstructive airway disease.
 - Albuterol syrup is approved for the relief of bronchospasm in adults and children 2 years of age and older with reversible obstructive airway disease.
 - Albuterol nebulizer solution is approved for the relief of bronchospasm in patients 2 years of age and older with reversible obstructive airway disease and acute attacks of bronchospasm.
 - Ipratropium/albuterol is approved for the treatment of bronchospasm associated with chronic obstructive pulmonary disease in patients requiring more than one bronchodilator.
 - Albuterol inhalation aerosol and ProAir Respiclick carry the same indications as Proventil HFA.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](#).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2019 Optum, Inc. All rights reserved.